Abstract
Simple SummaryThus far, no curative therapies are available for malignant SDHB-associated phaeochromocytomas and paragangliomas (PPGLs). Therapy development is severely hampered by the limited availability of suitable animal models. In this study, we investigated the potential of the sdhbrmc200 zebrafish model to study SDHB-associated PPGLs using a drug screening approach. One of the key features of cancer initiation and progression is redox imbalance. First, we identified increased reactive oxygen species levels in homozygous sdhbrmc200 larvae at baseline. Next, we tested the effect of anti- and pro-oxidant ascorbic acid (Vitamin C) on these larvae. We validated the sdhbrmc200 zebrafish model as a powerful drug screening tool to provide valuable insights into pathomechanisms, which may lead to novel therapeutic targets and therapy development in the future.Patients with mutations in the β-subunit of the succinate dehydrogenase (SDHB) have the highest risk to develop incurable malignant phaeochromocytomas and paragangliomas (PPGLs). Therapy development is hindered by limited possibilities to test new therapeutic strategies in vivo. One possible molecular mechanism of SDHB-associated tumorigenesis originates in an overproduction of reactive oxygen species (ROS) due to mitochondrial dysfunction. Ascorbic acid (Vitamin C) has already been shown to act as anti-cancer agent in several clinical trials for various types of cancer. In this study, the potential of the sdhbrmc200 zebrafish model to study SDHB-associated PPGLs using a drug screening approach was investigated. First, we identified increased basal ROS levels in homozygous sdhb larvae compared to heterozygous and wild-type siblings. Using a semi high-throughput drug screening, the effectiveness of different dosages of anti- and pro-oxidant Vitamin C were assessed to evaluate differences in survival, ROS levels, and locomotor activity. Low-dosage levels of Vitamin C induced a decrease of ROS levels but no significant effects on lifespan. In contrast, high-dosage levels of Vitamin C shortened the lifespan of the homozygous sdhbrmc200 larvae while not affecting the lifespan of heterozygous and wild-type siblings. These results validated the sdhbrmc200 zebrafish model as a powerful drug screening tool that may be used to identify novel therapeutic targets for SDHB-associated PPGLs.
Highlights
The mitochondrial enzymatic succinate dehydrogenase (SDH) complex, called mitochondrial complex II, has an essential role in ATP production
We investigated the potential of the sdhbrmc200 zebrafish model to study SDHB-associated phaeochromocytomas and paragangliomas (PPGLs) using a drug screen approach
We investigated redox homeostasis in larvae of the sdhbrmc200 zebrafish model, and we evaluated the effect of both low-dosage and high-dosage levels of Vitamin C by using an in vivo zebrafish drug screen
Summary
The mitochondrial enzymatic succinate dehydrogenase (SDH) complex, called mitochondrial complex II, has an essential role in ATP production. Pharmacologic levels of Vitamin C have been shown to aggravate the ROS-mediated toxicity in SDHBKD mouse phaeochromocytoma (MPC) cells, leading to genetic instability and apoptotic cell death [19] These SDHBKD MPC cells were injected into athymic nude mice, establishing metastatic PPGL tumours in vivo; the supplementation of high-dosage levels of Vitamin C strongly delayed metastatic lesions and thereby improved disease outcome [19]. A decreased mobility attributed to energy deficiency is observed These phenotypic read-outs in 6-day-old zebrafish larvae can be used to evaluate the effects of candidate drugs and could facilitate the (semi) high-throughput in vivo testing of potential therapeutic agents for SDHB-associated PPGLs. In this study, we investigated redox homeostasis in larvae of the sdhbrmc200 zebrafish model, and we evaluated the effect of both low-dosage and high-dosage levels of Vitamin C by using an in vivo zebrafish drug screen
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call